Abstract Title:

EGCG reducing the susceptibility to cholesterol gallstone formation through the regulation of inflammation.

Abstract Source:

Biomed Pharmacother. 2008 Dec;62(10):677-83. Epub 2008 Jan 30. PMID: 18374538

Abstract Author(s):

Dongmei Shan, Yishi Fang, Yiyi Ye, Jianwen Liu

Abstract:

In order to investigate whether (-)-Epigallocatechin-3-gallate (EGCG) can reduce the susceptibility to cholesterol gallstone formation in vivo, cholesterol gallstones mouse model was established with lithogenic diet. Compared with the Model group, the administration of EGCG (40 mg kg(-1)d(-1) and 80 mg kg(-1)d(-1), i.g., respectively) significantly reduced the gallstone formation rates and the serum lipid levels, also maintained the body weight at a relatively low level. Results of the microarray profiling assay showed the anti-inflammation effect of EGCG underlying affecting the hepatic metabolic pathway of cholesterol. Additionally, the expression of nuclear factor-kappaB (NF-kappaB) was down-regulated and the expression of peroxisome proliferator activated receptor gamma (PPARgamma) was up-regulated after the treatment of EGCG. Also, the expression of CYP7A1 was up-regulated after the treatment of EGCG. In conclusion, the findings of this study implied that EGCG can effectively reduce the susceptibility to cholesterol gallstone formation through the regulation of inflammation.

Study Type : Animal Study

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.